S&P 500   4,290.87 (-1.07%)
DOW   33,712.87 (-0.86%)
QQQ   355.81 (-1.06%)
AAPL   173.33 (-1.56%)
MSFT   312.70 (-1.52%)
META   298.38 (-0.81%)
GOOGL   128.40 (-2.07%)
AMZN   127.65 (-2.76%)
TSLA   246.03 (-0.39%)
NVDA   423.13 (+0.22%)
NIO   8.46 (+1.32%)
BABA   86.22 (-1.15%)
AMD   96.20 (-1.21%)
T   15.04 (-0.13%)
F   12.54 (-0.32%)
MU   68.45 (-0.19%)
CGC   0.94 (-0.84%)
GE   110.59 (-1.01%)
DIS   80.36 (-0.80%)
AMC   7.96 (-2.21%)
PFE   32.83 (-0.45%)
PYPL   59.06 (+0.34%)
NFLX   380.88 (-1.02%)
S&P 500   4,290.87 (-1.07%)
DOW   33,712.87 (-0.86%)
QQQ   355.81 (-1.06%)
AAPL   173.33 (-1.56%)
MSFT   312.70 (-1.52%)
META   298.38 (-0.81%)
GOOGL   128.40 (-2.07%)
AMZN   127.65 (-2.76%)
TSLA   246.03 (-0.39%)
NVDA   423.13 (+0.22%)
NIO   8.46 (+1.32%)
BABA   86.22 (-1.15%)
AMD   96.20 (-1.21%)
T   15.04 (-0.13%)
F   12.54 (-0.32%)
MU   68.45 (-0.19%)
CGC   0.94 (-0.84%)
GE   110.59 (-1.01%)
DIS   80.36 (-0.80%)
AMC   7.96 (-2.21%)
PFE   32.83 (-0.45%)
PYPL   59.06 (+0.34%)
NFLX   380.88 (-1.02%)
S&P 500   4,290.87 (-1.07%)
DOW   33,712.87 (-0.86%)
QQQ   355.81 (-1.06%)
AAPL   173.33 (-1.56%)
MSFT   312.70 (-1.52%)
META   298.38 (-0.81%)
GOOGL   128.40 (-2.07%)
AMZN   127.65 (-2.76%)
TSLA   246.03 (-0.39%)
NVDA   423.13 (+0.22%)
NIO   8.46 (+1.32%)
BABA   86.22 (-1.15%)
AMD   96.20 (-1.21%)
T   15.04 (-0.13%)
F   12.54 (-0.32%)
MU   68.45 (-0.19%)
CGC   0.94 (-0.84%)
GE   110.59 (-1.01%)
DIS   80.36 (-0.80%)
AMC   7.96 (-2.21%)
PFE   32.83 (-0.45%)
PYPL   59.06 (+0.34%)
NFLX   380.88 (-1.02%)
S&P 500   4,290.87 (-1.07%)
DOW   33,712.87 (-0.86%)
QQQ   355.81 (-1.06%)
AAPL   173.33 (-1.56%)
MSFT   312.70 (-1.52%)
META   298.38 (-0.81%)
GOOGL   128.40 (-2.07%)
AMZN   127.65 (-2.76%)
TSLA   246.03 (-0.39%)
NVDA   423.13 (+0.22%)
NIO   8.46 (+1.32%)
BABA   86.22 (-1.15%)
AMD   96.20 (-1.21%)
T   15.04 (-0.13%)
F   12.54 (-0.32%)
MU   68.45 (-0.19%)
CGC   0.94 (-0.84%)
GE   110.59 (-1.01%)
DIS   80.36 (-0.80%)
AMC   7.96 (-2.21%)
PFE   32.83 (-0.45%)
PYPL   59.06 (+0.34%)
NFLX   380.88 (-1.02%)
Most-Upgraded StocksMost-Upgraded
NASDAQ:NBIX

Neurocrine Biosciences (NBIX) Stock Forecast, Price & News

$114.10
+0.42 (+0.37%)
(As of 01:08 PM ET)
Compare
Today's Range
$113.45
▼
$115.35
50-Day Range
$97.20
▼
$117.10
52-Week Range
$89.04
▼
$129.29
Volume
171,880 shs
Average Volume
760,430 shs
Market Capitalization
$11.14 billion
P/E Ratio
65.95
Dividend Yield
N/A
Price Target
$128.52
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Neurocrine Biosciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.76 Rating Score
Upside/​Downside
12.8% Upside
$128.52 Price Target
Short Interest
Healthy
2.07% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.61
Upright™ Environmental Score
News Sentiment
0.97mentions of Neurocrine Biosciences in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$3.24 M Sold Last Quarter
Proj. Earnings Growth
121.36%
From $2.20 to $4.87 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.81 out of 5 stars

Medical Sector

64th out of 961 stocks

Biological Products, Except Diagnostic Industry

7th out of 161 stocks

See Top Rated MarketRank™ Stocks Here

NBIX stock logo

About Neurocrine Biosciences (NASDAQ:NBIX) Stock

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its products include INGREZZA and DYSVAL, for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, used as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women, as well as ALKINDI SPRINKLE, for the treatment of pediatric adrenal insufficiency. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-1117568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; Sentia Medical Sciences Inc.; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

NBIX Price History

NBIX Stock News Headlines

September 24, 2023 | americanbankingnews.com
Neurocrine Biosciences (NASDAQ:NBIX) Rating Increased to Strong-Buy at StockNews.com
September 23, 2023 | americanbankingnews.com
Barclays Increases Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $134.00
September 26, 2023 | Micro-Cap Stock Trader (Ad)
U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
September 21, 2023 | markets.businessinsider.com
Promising CAHtalyst Study Results and Anticipated Crinecerfont Uptake Drive Analyst’s ‘Buy’ Rating for Neurocrine
September 21, 2023 | finance.yahoo.com
Neurocrine Biosciences Presents Post Hoc Data Analysis in Congenital Adrenal Hyperplasia at ESPE 2023
September 16, 2023 | americanbankingnews.com
Neurocrine Biosciences (NASDAQ:NBIX) Rating Lowered to Buy at StockNews.com
September 16, 2023 | americanbankingnews.com
Wedbush Analysts Boost Earnings Estimates for Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
September 16, 2023 | americanbankingnews.com
Analysts Set Expectations for Neurocrine Biosciences, Inc.'s Q3 2023 Earnings (NASDAQ:NBIX)
September 26, 2023 | Micro-Cap Stock Trader (Ad)
Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
September 14, 2023 | finance.yahoo.com
Director Gary Lyons Sells 5,000 Shares of Neurocrine Biosciences Inc (NBIX)
September 14, 2023 | markets.businessinsider.com
Neurocrine : FDA Accepts NDA For Ingrezza Oral Granules Sprinkle Formulation
September 14, 2023 | finance.yahoo.com
Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Application for INGREZZA® (valbenazine) Oral Granules Sprinkle Formulation
September 13, 2023 | markets.businessinsider.com
Analysts Are Bullish on Top Healthcare Stocks: Neurocrine (NBIX), HCA Healthcare (HCA)
September 13, 2023 | markets.businessinsider.com
H.C. Wainwright Sticks to Its Buy Rating for Neurocrine (NBIX)
September 12, 2023 | markets.businessinsider.com
Neurocrine (NBIX) Receives a Buy from Goldman Sachs
September 12, 2023 | msn.com
What's Going On With Neurocrine Biosciences Stock Today?
September 12, 2023 | finance.yahoo.com
Neurocrine Biosciences Inc's Meteoric Rise: Unpacking the 22% Surge in Just 3 Months
September 12, 2023 | finance.yahoo.com
Can Neurocrine Erase Its Recent Setbacks With This Jump To An Eight-Month High?
September 12, 2023 | markets.businessinsider.com
Neurocrine Biosciences Reports Positive Top-line Data From Phase 3 Study Of Crinecerfont
September 12, 2023 | finance.yahoo.com
Neurocrine Biosciences Announces Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia (CAH)
September 11, 2023 | finance.yahoo.com
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
August 31, 2023 | finance.yahoo.com
Neurocrine Biosciences to Present at Upcoming Investor Conferences in September
August 29, 2023 | finance.yahoo.com
Neurocrine Biosciences Presents Data at MDS International Congress of Parkinson's Disease and Movement Disorders® Demonstrating Comparable Improvement Over Time in Tardive Dyskinesia Severity and Impact Following Treatment With INGREZZA® (valbenazine) Capsules
August 28, 2023 | markets.businessinsider.com
Neurocrine Reveals New Data On Ingrezza With Improvements In HD Chorea In Huntington's Disease
August 28, 2023 | finance.yahoo.com
Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Capsules Data Demonstrating Early and Sustained Improvements in Chorea Associated With Huntington's Disease
August 25, 2023 | msn.com
Neurocrine Needs A Meaningful Clinical Win To Break Out, And Crinecerfont Could Do It
August 22, 2023 | msn.com
Cantor Fitzgerald Reiterates Neurocrine Biosciences (NBIX) Overweight Recommendation
See More Headlines
Receive NBIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter.

NBIX Company Calendar

Last Earnings
8/01/2023
Today
9/26/2023
Next Earnings (Estimated)
11/07/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:NBIX
CUSIP
64125C10
CIK
914475
Web
www.neurocrine.com
Phone
(858) 617-7600
Fax
858-617-7602
Employees
1,200
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$128.52
High Stock Price Forecast
$154.00
Low Stock Price Forecast
$95.00
Forecasted Upside/Downside
+12.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.76
Research Coverage
21 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$1.73
Trailing P/E Ratio
65.87
Forward P/E Ratio
51.80
P/E Growth
1.12
Net Income
$154.50 million
Net Margins
10.54%
Pretax Margin
13.99%
Return on Equity
10.39%
Return on Assets
7.44%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.57
Quick Ratio
2.51

Sales & Book Value

Annual Sales
$1.49 billion
Price / Sales
7.48
Cash Flow
$1.79 per share
Price / Cash Flow
63.83
Book Value
$17.76 per share
Price / Book
6.42

Miscellaneous

Outstanding Shares
97,650,000
Free Float
93,160,000
Market Cap
$11.13 billion
Optionable
Optionable
Beta
0.46
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. Kevin C. Gorman Ph.D. (Age 65)
    CEO & Director
    Comp: $1.9M
  • Mr. Matthew C. Abernethy (Age 43)
    Chief Financial Officer
    Comp: $1.04M
  • Mr. Darin M. Lippoldt Esq. (Age 57)
    Chief Legal Officer & Corp. Sec.
    Comp: $921.01k
  • Mr. Kyle W. Gano Ph.D. (Age 50)
    Chief Bus. Devel. and Strategy Officer
    Comp: $921.52k
  • Dr. Eiry Wyn Roberts M.D. (Age 59)
    Chief Medical Officer
    Comp: $1.04M
  • Dr. Jude Onyia Ph.D. (Age 59)
    Chief Scientific Officer
  • Jane Sorensen
    Head of Investor Relations
  • Ms. Julie S. CookeMs. Julie S. Cooke (Age 57)
    Chief HR Officer
  • Mr. Eric S. BenevichMr. Eric S. Benevich (Age 58)
    Chief Commercial Officer
  • Mr. David Warren Boyer (Age 44)
    Chief Corp. Affairs Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













NBIX Stock - Frequently Asked Questions

Should I buy or sell Neurocrine Biosciences stock right now?

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last twelve months. There are currently 5 hold ratings and 16 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" NBIX shares.
View NBIX analyst ratings or view top-rated stocks.

What is Neurocrine Biosciences' stock price forecast for 2023?

21 brokerages have issued twelve-month price targets for Neurocrine Biosciences' shares. Their NBIX share price forecasts range from $95.00 to $154.00. On average, they predict the company's share price to reach $128.52 in the next twelve months. This suggests a possible upside of 12.8% from the stock's current price.
View analysts price targets for NBIX or view top-rated stocks among Wall Street analysts.

How have NBIX shares performed in 2023?

Neurocrine Biosciences' stock was trading at $119.44 at the beginning of 2023. Since then, NBIX stock has decreased by 4.6% and is now trading at $113.96.
View the best growth stocks for 2023 here.

When is Neurocrine Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023.
View our NBIX earnings forecast.

How were Neurocrine Biosciences' earnings last quarter?

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) released its earnings results on Tuesday, August, 1st. The company reported $0.95 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.77 by $0.18. The firm earned $452.70 million during the quarter, compared to the consensus estimate of $448.29 million. Neurocrine Biosciences had a net margin of 10.54% and a trailing twelve-month return on equity of 10.39%.

What ETFs hold Neurocrine Biosciences' stock?

ETFs with the largest weight of Neurocrine Biosciences (NASDAQ:NBIX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), First Trust NYSE Arca Biotechnology Index Fund (FBT), Invesco Biotechnology & Genome ETF (PBE), Goldman Sachs Future Health Care Equity ETF (GDOC), Invesco S&P MidCap Momentum ETF (XMMO), Virtus LifeSci Biotech Products ETF (BBP), Invesco S&P MidCap 400 Pure Growth ETF (RFG) and SPDR S&P Biotech ETF (XBI).

What is Kevin C. Gorman's approval rating as Neurocrine Biosciences' CEO?

11 employees have rated Neurocrine Biosciences Chief Executive Officer Kevin C. Gorman on Glassdoor.com. Kevin C. Gorman has an approval rating of 97% among the company's employees. This puts Kevin C. Gorman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Neurocrine Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Netflix (NFLX), AbbVie (ABBV), Walt Disney (DIS), Tesla (TSLA), Block (SQ) and Salesforce (CRM).

What is Neurocrine Biosciences' stock symbol?

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

Who are Neurocrine Biosciences' major shareholders?

Neurocrine Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (13.81%), State Street Corp (4.05%), Bellevue Group AG (2.68%), Renaissance Technologies LLC (1.68%), Bank of New York Mellon Corp (1.63%) and Geode Capital Management LLC (1.56%). Insiders that own company stock include Darin Lippoldt, David W Boyer, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Ingrid Delaet, Jude Onyia, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, Neurocrine Biosciences Inc, Richard F Pops, Stephen A Sherwin and William H Rastetter.
View institutional ownership trends.

How do I buy shares of Neurocrine Biosciences?

Shares of NBIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Neurocrine Biosciences' stock price today?

One share of NBIX stock can currently be purchased for approximately $113.96.

How much money does Neurocrine Biosciences make?

Neurocrine Biosciences (NASDAQ:NBIX) has a market capitalization of $11.13 billion and generates $1.49 billion in revenue each year. The company earns $154.50 million in net income (profit) each year or $1.73 on an earnings per share basis.

How many employees does Neurocrine Biosciences have?

The company employs 1,200 workers across the globe.

How can I contact Neurocrine Biosciences?

Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The official website for the company is www.neurocrine.com. The company can be reached via phone at (858) 617-7600, via email at ir@neurocrine.com, or via fax at 858-617-7602.

This page (NASDAQ:NBIX) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -